Spruce Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SPRB research report →
Range $104 – $150
Price Chart
About the company
Spruce Biosciences, Inc. , founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions.
- CEO
- Javier Szwarcberg
- IPO
- 2020
- Employees
- 14
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on SPRB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $143.08M
- P/E
- -1.27
- Fwd P/E
- 16.69
- PEG
- -0.02
- P/S
- 0.00
- P/B
- 1.51
- EV/EBITDA
- -1.12
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -123.53%
- ROIC
- -50.49%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0-100.0%
- Op Income
- $-36,513,000
- Net Income
- $-38,966,000+26.5%
- EPS
- $-50.83+47.5%
- OCF Growth
- +40.4%
- FCF Growth
- +40.4%
- 52W High
- $240.00
- 52W Low
- $7.00
- 50D MA
- $48.46
- 200D MA
- $66.86
- Beta
- 3.34
- RSI (14)
- 63
- Avg Volume
- 64.18K
No earnings-call transcripts are available for SPRB yet.
- Free Float
- 78.7%
- Shares Outstanding
- 2.75M
- Float Shares
- 2.16M
of shares held by institutions
32 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 17.87K | ▲ 17.87K |
Held by 68 ETFs
Biggest fund positions in SPRB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 27, 26 | Quartel Adrian W | other | 13,000 |
| Jul 27, 26 | Quartel Adrian W | other | 0 |
| Jun 30, 26 | Szwarcberg Javier B. | other | 266 |
| May 21, 26 | SPIEGELMAN DANIEL K | other | 1,700 |
| May 21, 26 | SIMPSON CAMILLA V | other | 1,700 |
| May 21, 26 | GREY MICHAEL G | other | 1,700 |
| May 21, 26 | Barretto-Ko Percival | other | 1,700 |
| May 21, 26 | Walbert Keli | other | 1,700 |
| Mar 9, 26 | Hooks Corwin Dale | other | 11,000 |
| Mar 9, 26 | Hooks Corwin Dale | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SPRB coverage
Recent articles, reports, and earnings notes.
No research on SPRB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SPRB report →Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences
gurufocus.com · Aug 12
Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
businesswire.com · Aug 12
Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences
businesswire.com · Aug 12
Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development
businesswire.com · Aug 3
Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer
businesswire.com · Jul 27
Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
businesswire.com · Jul 8
Spruce Biosciences Possibly First In-MPS IIIB Class Enzyme Replacement Therapy
seekingalpha.com · Jul 8
Spruce Biosciences Joins the Russell 3000® Index
gurufocus.com · Jun 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.